Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches - Report - MDSpire

Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches

  • By

  • Chiara Moltrasio

  • Abbas Khan

  • Namra Ahmad

  • Muhammad Adil Malik

  • Paola Maura Tricarico

  • Sergio Crovella

  • Abdelali Agouni

  • Angelo Valerio Marzano

  • May 25, 2026

  • 0 min

Share

Clinical Report: Chronic Inflammation in Hidradenitis Suppurativa

Overview

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder linked to systemic inflammation and metabolic dysfunction. This report highlights the role of meta-inflammation in HS pathogenesis and discusses potential therapeutic strategies targeting this condition.

Background

Hidradenitis suppurativa is a prevalent inflammatory skin disorder that significantly impacts patients' quality of life due to its painful and debilitating symptoms. Recent insights suggest that HS is not merely a localized condition but is associated with systemic inflammatory states, particularly metabolic syndrome. Understanding the interplay between HS and metabolic dysfunction is crucial for developing effective treatment strategies.

Data Highlights

No specific numerical data was provided in the source material.

Key Findings

  • HS is characterized by recurrent nodules, abscesses, and sinus tracts in apocrine gland-bearing skin.
  • Meta-inflammation links HS with metabolic syndrome, driven by pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6.
  • Chronic low-grade inflammation from metabolic disturbances exacerbates HS severity and associated comorbidities.
  • Targeting meta-inflammation through lifestyle changes and immuno-metabolic therapies may improve clinical outcomes in HS patients.
  • HS is increasingly recognized as a systemic inflammatory condition with significant associations with various comorbidities.

Clinical Implications

Healthcare professionals should consider HS as a systemic inflammatory disorder and assess for metabolic comorbidities in affected patients. Integrating lifestyle modifications and immuno-metabolic therapies into treatment plans may enhance patient outcomes and address underlying inflammatory mechanisms.

Conclusion

The understanding of meta-inflammation's role in HS provides valuable insights for developing comprehensive treatment strategies. A multidisciplinary approach targeting both skin inflammation and metabolic dysfunction is essential for improving patient care.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review
  2. JAMA Dermatology, 2025 -- Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase
  3. Dermatology and Therapy, 2026 -- The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review
  4. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment - PubMed
  5. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial - PubMed
  6. Contact Lens Spectrum — ONLINE PHOTO DIAGNOSIS
  7. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment - PubMed
  8. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial - PubMed
  9. Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa | Incyte

Original Source(s)

Related Content